Revance Therapeutics, a biotechnology company specializing in neuromodulator innovations, recently announced a U.S. distribution agreement with Swiss hyaluronic acid (HA)-based dermal filler manufacturing company, TEOXANE SA.
The partnership gives Revance immediate and exclusive access to the company’s range of Resilient HA (RHA) fillers in the United States, with TEOXANE gaining 2.5 million shares of Revance common stock in return, according to the press release.
Along with TEOXANE’s Food and Drug Administration (FDA)-approved RHA 2, RHA 3 and RHA 4 products that include lidocaine, it also includes a fourth product, RHA 1, which is currently in clinical trials, with anticipated FDA approval in 2021.
TEOXANE says their patented RHA crosslinking method preserves the HA network for correction of moderate to severe facial wrinkles and folds and optimizes strength, stretch and tissue integration.
“We are eager to introduce U.S. physicians and consumers to our exciting, highly differentiated RHA range of dermal fillers,” says Valerie Taupin, founder and chief executive officer of TEOXANE.
Revance believes that adding the RHA line of products to its own neuromodulator, DaxibotulinumtoxinA (DAXI), which combines a “proprietary stabilizing peptide excipient with a highly purified botulinum toxin without human or animal-based components,” will position them as a leader in the $2 billion U.S. facial injectable market.